WellDyneRx, an independent Pharmacy Benefit Manager involved in delivering solutions through integrated data and technology, has named Jeff Park as its new chairman and chief executive officer of the company, it was reported yesterday.
Park is the former executive vice president and chief operating officer of Catamaran, which is now called optumRx. During his tenure, Catamaran grew from USD55m in revenues to a Fortune 500 public company with over USD21bn in revenues before it was acquired by United Health Group in 2015.
WellDyneRx lead director, Eric Elliott, said, 'We are excited to have Jeff join WellDyneRx president, Zach Johnson, and the rest of our leadership team. Jeff's strategic vision and operating expertise support our growth plans. Our extensive search for the right executive produced a great result. Now, with a strong team in place, we expect our value proposition in the constantly changing PBM sector to resonate even more clearly, and growth will accelerate.'
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation